An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging

被引:15
|
作者
Wanet, Marie [1 ]
Delor, Antoine [2 ]
Hanin, Francois-Xavier [3 ]
Ghaye, Benoit [4 ]
Van Maanen, Aline [5 ]
Remouchamps, Vincent [6 ]
Clermont, Christian [6 ]
Goossens, Samuel [1 ]
Lee, John Aldo [1 ]
Janssens, Guillaume [1 ]
Bol, Anne [1 ]
Geets, Xavier [1 ]
机构
[1] Catholic Univ Louvain, Inst Rech Expt & Clin, Ctr Mol Imaging Radiotherapy & Oncol MIRO, Ave Hippocrate,54 Bte B1-54-07, B-1200 Brussels, Belgium
[2] Clin Univ St Luc, Dept Radiat Oncol, B-1200 Brussels, Belgium
[3] Clin Univ St Luc, Dept Nucl Med, B-1200 Brussels, Belgium
[4] Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium
[5] Clin Univ St Luc, Stat Support Unit, Canc Ctr, B-1200 Brussels, Belgium
[6] CHU UCL Namur, Dept Radiat Oncol, Clin & Maternite St Elisabeth Namur, B-5000 Namur, Belgium
关键词
Non-small cell lung cancer; Dose escalation; FDG-PET imaging; Intensity modulated radiotherapy; Toxicity; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; ELECTIVE NODAL IRRADIATION; NORMAL TISSUE CONSTRAINTS; THERAPY ONCOLOGY GROUP; PHASE-II; CONCURRENT CHEMORADIATION; THORACIC RADIOTHERAPY; RESPONSE EVALUATION; NSCLC PATIENTS; SOLID TUMORS;
D O I
10.1007/s00066-017-1168-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim The aim of the study was to assess the feasibility of an individualized 18F fluorodeoxyglucose positron emission tomography (FDG-PET)-guided dose escalation boost in non-small cell lung cancer (NSCLC) patients and to assess its impact on local tumor control and toxicity. Patients and methods total of 13 patients with stage II-III NSCLC were enrolled to receive a dose of 62.5 Gy in 25 fractions to the CT-based planning target volume (PTV; primary turmor and affected lymph nodes). The fraction dose was increased within the individual PET-based PTV (PTVPET) using intensity modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) until the predefined organ-at-risk (OAR) threshold was reached. Tumor response was assessed during follow-up by means of repeat FDG-PET/computed tomography. Acute and late toxicity were recorded and classified according to the CTCAE criteria (Version 4.0). Local progression-free survival was determined using the Kaplan-Meier method. Results The average dose to PTVPET reached 89.17 Gy for peripheral and 75 Gy for central tumors. After a median follow-up period of 29 months, seven patients were still alive, while six had died (four due to distant progression, two due to grade 5 toxicity). Local progression was seen in two patients in association with further recurrences. One and 2-year local progression free survival rates were 76.9% and 52.8%, respectively. Three cases of acute grade 3 esophagitis were seen. Two patients with central tumors developed late toxicity and died due to severe hemoptysis. Conclusion hese results suggest that a non-uniform and individualized dose escalation based on FDG-PET in IMRT delivery is feasible. The doses reached were higher in patients with peripheral compared to central tumors. This strategy enables good local control to be achieved at acceptable toxicity rates. However, dose escalation in centrally located tumors with direct invasion of mediastinal organs must be performed with great caution in order to avoid severe late toxicity.
引用
收藏
页码:812 / 822
页数:11
相关论文
共 50 条
  • [31] A planning study of proton therapy dose escalation for non-small cell lung cancer
    Hessels, Arno C.
    Visser, Sabine
    Both, Stefan
    Korevaar, Erik W.
    Langendijk, Johannes A.
    Wijsman, Robin
    PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2024, 31
  • [32] Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer
    Nijkamp, Jasper
    Rossi, Maddalena
    Lebesque, Joos
    Belderbos, Jose
    van den Heuvel, Michel
    Kwint, Margriet
    Uyterlinde, Wilma
    Vogel, Wouter
    Sonke, Jan-Jakob
    RADIOTHERAPY AND ONCOLOGY, 2013, 106 (01) : 118 - 123
  • [33] FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
    Mitsunori Higuchi
    Yuki Owada
    Takuya Inoue
    Yuzuru Watanabe
    Takumi Yamaura
    Mitsuro Fukuhara
    Takeo Hasegawa
    Hiroyuki Suzuki
    World Journal of Surgical Oncology, 14
  • [34] Dose escalation for non-small cell lung cancer: Analysis and modelling of published literature
    Partridge, Mike
    Ramos, Monica
    Sardaro, Angela
    Brada, Michael
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 (01) : 6 - 11
  • [35] Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC)
    Edet-Sanson, Agathe
    Dubray, Bernard
    Doyeux, Kaya
    Back, Adeline
    Hapdey, Sebastien
    Modzelewski, Romain
    Bohn, Pierre
    Gardin, Isabelle
    Vera, Pierre
    RADIOTHERAPY AND ONCOLOGY, 2012, 102 (02) : 251 - 257
  • [36] Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer
    Lee, Ho-Young
    Chung, June-Key
    Jeong, Jae Min
    Lee, Dong Soo
    Kim, Dong Gyu
    Jung, Hee Won
    Lee, Myung Chul
    ANNALS OF NUCLEAR MEDICINE, 2008, 22 (04) : 281 - 286
  • [37] Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer
    Ho-Young Lee
    June-Key Chung
    Jae Min Jeong
    Dong Soo Lee
    Dong Gyu Kim
    Hee Won Jung
    Myung Chul Lee
    Annals of Nuclear Medicine, 2008, 22
  • [38] Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure
    Mac Manus, MP
    Hicks, RJ
    Matthews, JP
    Wirth, A
    Rischin, D
    Ball, DL
    LUNG CANCER, 2005, 49 (01) : 95 - 108
  • [39] A new approach to dose escalation in non-small-cell lung cancer
    Mehta, M
    Scrimger, R
    Mackie, R
    Paliwal, B
    Chappell, R
    Fowler, J
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (01): : 23 - 33
  • [40] Clinical Perspectives on Dose Escalation for Non-Small-Cell Lung Cancer
    Chang, Albert J.
    Bradley, Jeffrey D.
    CLINICAL LUNG CANCER, 2010, 11 (05) : 299 - 302